DailyUpdates by e-mail - the publication & News tracker for the drug discovery community

Combining proprietary data retrieval strategies with the expertise of an industrial selection panel DailyUpdates delivers selected breaking journal articles & press releases. Now available through six therapeutic channels match core R&D areas

Oncology Channel; CNS disorders; Cardiovascular disease; Metabolic and Hormonal disorders; Immunology, Inflammation & Infection; Internal Medicine.
If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Today's top news stories

Roche Q1 sales beat forecasts as Pegasys flies

Schering-Plough Submits New Drug Application (J-NDA) in Japan for PEG-INTRON(R) and REBETOL(R) Combination Therapy for Hepatitis C
(Ed: For a full analysis of developments in the HCV therapeutics arena click here)

Inspire Pharmaceuticals Developing Novel Approach for Treatment of Retinal Detachment

Southwest Oncology Group Initiates Phase 2 Clinical Trial Using Introgen's Advexin(R) Cancer Therapy

Metaphore Pharmaceuticals, Inc. to Present New Phase II Clinical Data at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference

US FDA OKs Bertek drug for Parkinson's immobility
(Ed: For a full analysis of neurodegenerative disorders R&D activity click here or here)

All of today's news stories updated every 30 minutes

For targeted press releases subscribe below

Submit your press release or have LeadDiscovery produce a release for you

PharmaReports

Click here to search our full list of PharmaReports

Submit your publication to DailyUpdates

To subscribe - click here! 

Subscription to targeted DailyUpdates channels

  • Oncology
  • CNS disorders
  • Cardiovascular disease
  • Metabolic & Hormonal disorders
  • Immunology, Inflammation & Infection
  • Internal Medicine (GI, GU & Intestinal tracts)

Most recent journal article entries

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15;100(8):1692-8.

PharmaReport Alert: Alzheimer disease - new drugs, markets and companies Click here for executive summary

Bone and joint neuropathy in rats with type-2 diabetes. Regul Pept. 2004 Jun 15;119(1-2):61-7.

Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004 Apr 13;109(14):1704-6. Epub 2004 Apr 05.

The role of Ca(2+) channel modulation in the neuroprotective actions of estrogen in beta-amyloid protein and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) cytotoxic models. Neurochem Int. 2004 Jul;45(1):31-8.

Khellinone Derivatives as Blockers of the Voltage-Gated Potassium Channel Kv1.3: Synthesis and Immunosuppressive Activity. J Med Chem. 2004 Apr 22;47(9):2326-2336.

Segregation of two glutaminase isoforms in islets of Langerhans. Biochem J. 2004 Apr 19 [Epub ahead of print].

A novel anti-oxidant and anti-cancer strategy: a peptoid anti-inflammatory drug conjugate with SOD mimic activity. Biochem Biophys Res Commun. 2004 May 14;317(4):1155-8.

Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.

4-(Tetralin-1-yl)- and 4-(Naphthalen-1-yl)alkyl Derivatives of 1-Cyclohexylpiperazine as sigma Receptor Ligands with Agonist sigma(2) Activity. J Med Chem. 2004 Apr 22;47(9):2308-17.

The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial. Am J Gastroenterol. 2004 Apr;99(4):611-8.
(Ed:This PharmaReport evaluates COX-2 inhibitors however readers may also be interested in our feature on disease modifying drugs in development for osteoarthritis [click here for more])

Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol. 2004 Apr 5;489(1-2):93-100.

Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004 Apr;19(8):871-8.

Design, Synthesis, and Biological Evaluation of Substituted 2-Cyclohexyl-4-phenyl-1H-imidazoles: Potent and Selective Neuropeptide Y Y5-Receptor Antagonists. J Med Chem. 2004 Apr 22;47(9):2318-2325.

5-Alpha Reductase Inhibition Provides Superior Benefits to Alpha Blockade by Preventing AUR and BPH-Related Surgery. Eur Urol. 2004 May;45(5):620-7.
(Ed:This PharmaReport evaluates therapeutics surrounding male health care and includes a major section on BPH)

Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur J Pharmacol. 2004 Apr 19;490(1-3):159-68.
(Ed:In addition to these PharmaReports on diabetes we are currently featuring a report focusing on concurrent treatment of diabetes and cardiovascular disorders (click here) and another that evaluates cardiovascular risk factors such as diabetes (click here)

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol. 2004 May;53(5):452-7. Epub 2004 Jan 17.
(Ed: These PharmaReports focus on drug delivery technology. The first report is specific for cancer drug delivery; the second is a more general evaluation of novel drug delivery technologies)

Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 Apr 15 [Epub ahead of print].
(Ed:This PharmaReport evaluates therapeutics surrounding male health care and includes a major section on erectile dysfunction)

The insulinotropic agent ID1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab. 2004 Apr 13 [Epub ahead of print].

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004 Apr 8;350(15):1505-15.
(Ed:In addition to these general PharmaReports on dyslipidemia we are currently featuring a report focusing on concurrent treatment of diabetes and dyslipidemia [click here for more])

visit archive

Selected analyses of pharmaceutical/market development relating to today's selected publications (click on title or the icon next to publications listed above):

This email has been circulated by BioPortfolio Ltd on behalf of LeadDiscovery Limited. As a registered user of the BioPortfolio web sites, you were selected to receive this message in the genuine belief that it would be of interest to you.

Subscriber information:
To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com WITH NO SUBJECT.  The system will automatically remove your email address from the list based on your email address.  If your email has changed please email peter.barfoot@bioportfolio.com with a list of your email address and we will manually unsubscribe for you.  Thank you for your understanding.

To subscribe for the BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com

Disclaimer:
BioPortfolio Limited and its agents used their best efforts in collecting and preparing the information published herein. However, BioPortfolio does not assume, and hereby disclaims, any and all liability for any loss or damage caused by errors, whether such errors resulted from negligence, accident, or other causes. All rights reserved. ©2004 BioPortfolio Limited.
 

BioPortfolio is the essential web resource for scientists, executives, investors and the consumer with an interest in who, what, where, when and why biotechnology will impact on our lives. We have created proprietary databases and search engines that will support your business and private interests in the most exiting technology of the 21st Century. BioPortfolio provides 14 Channels: www.bioportfolio.com/